Akebia Therapeutics Reports Strong Vafseo Growth Amid Pipeline Advances
Event summary
- Vafseo net product revenues grew to $15.8 million in Q1 2026, up from $12.0 million in Q1 2025.
- Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025.
- Akebia initiated a Phase 2 clinical trial of praliciguat for focal segmental glomerulosclerosis (FSGS).
- Akebia expects topline data from VOCAL Phase 3b trial in Q4 2026 and VOICE Phase IV trial in early 2027.
- Net loss was $9.1 million in Q1 2026, compared to net income of $6.1 million in Q1 2025.
The big picture
Akebia Therapeutics is making strides in both commercial and pipeline fronts, with Vafseo showing strong growth in patient numbers and revenues. The company's focus on expanding its pipeline with new clinical trials for rare kidney diseases positions it to potentially become a leader in the kidney disease treatment space. However, the financial performance remains a challenge as the company navigates increasing expenses and declining revenues from Auryxia due to generic competition.
What we're watching
- Commercial Momentum
- Whether Akebia can sustain the 60% patient growth rate for Vafseo and expand its prescriber base beyond dialysis organizations.
- Pipeline Progress
- The pace at which Akebia advances its clinical pipeline, particularly the Phase 2 trial of praliciguat and the planned Phase 2 basket study of AKB-097.
- Financial Performance
- How Akebia manages its increasing expenses and whether it can achieve profitability amid declining Auryxia revenues.
Related topics